Best Practices in Lung Cancer – November 2017 Vol 8
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
In this Special Edition, we direct our attention to lung cancer and the positive impact navigators have had in this disease state.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
In an effort to understand a day in the life of a thoracic navigator, we spent some time with Wendy Brooks, RN, ONN-CG. Ms Brooks obtained her certification as generalist oncology nurse navigator through the Academy of Oncology Nurse & Patient Navigators (AONN+) and was instrumental in the development of the AONN+ specialty certification exam in thoracic oncology.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
To be effective, navigators are required to stay up to date on the constantly changing landscape of lung cancer care.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
It has been proved that teamwork is vital in the battle against cancer. This is a fact that the Academy of Oncology Nurse & Patient Navigators (AONN+) and the American Cancer Society (ACS) recently validated when they entered into a National Alliance Partnership Program.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
Osimertinib improves progression-free survival by 54% compared with standard first-line therapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented at the ESMO 2017 Congress in Madrid.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
Durvalumab, a PD-L1 inhibitor, improved progression-free survival (PFS) by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) that did not progress after standard treatment with chemoradiotherapy, according to results presented at the ESMO 2017 Congress.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
Findings of a randomized study suggest that follow-up CT scans may not be needed every 3 to 6 months during the first 2 years after surgery for patients with non–small cell lung cancer (NSCLC).
Results 1 - 7 of 7